EUVIMEDEUVIMED entdecken
Crossref

PD04.08. Impact of Locoregional Treatment in Synchronous Oligometastatic Esophageal Cancer: Evidence From a Real-World Cohort

Matteo Pittacolo, Lucia Moletta, Arianna Vittori, Giovanni Capovilla, Giulia Nezi, Luca Provenzano, Gianpietro Zanchettin, Elisa Sefora Pierobon, Sabina Murgioni, Floriana Nappo, Sara Lonardi, Renato Salvador und 1 weitere

Diseases of the Esophagus · 22.08.2026 · 39 (Supplement_1)

DOI: 10.1093/dote/doag077.103 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diseases of the Esophagus, online erschienen am 22.08.2026. Verfasst von Matteo Pittacolo und 12 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Topic Esophageal Cancer: Management of Metastatic Cancer Background In metastatic esophageal cancer, systemic therapy is standard of care. The oligometastatic paradigm suggests that selected patients with limited metastatic burden may benefit from multimodal strategies including metastasis-directed locoregional therapy. Comparative data in synchronous oligometastatic esophageal/GEJ cancer remain limited.

Methods

We performed a single-center retrospective cohort study (2015–2025) including patients with synchronous oligometastatic esophageal/GEJ adenocarcinoma (AC) or squamous cell carcinoma (SCC), defined according to OMEC criteria (≤3 metastases in one organ or one extra-regional nodal station). Patients received systemic therapy alone (ST) or systemic therapy plus metastasis-directed locoregional treatment (LT; surgery, ablation, or stereotactic/conformal radiotherapy). Overall survival (OS) and progression-free survival (PFS) were estimated using Kaplan–Meier methods and compared with log-rank testing. Cox regression was used to identify prognostic factors.

Results

Fifty-three patients were eligible (ST n=32; LT n=21). Median OS was 19.1 months with LT versus 9.7 months with ST (HR 0.52, 95% CI 0.27–1.00; p=0.049). Median PFS was 18.0 versus 7.5 months, respectively (HR 0.40, 95% CI 0.21–0.74; p=0.0028). Histology-stratified analyses suggested a differential effect: in SCC, LT was associated with improved OS (HR 0.27; p=0.03) and PFS (HR 0.16; p=0.003), whereas no significant differences were observed in AC (OS HR 0.81; p=0.61; PFS HR 0.67; p=0.32). On multivariable analysis, LT remained independently associated with improved OS (HR 0.28; p=0.037) and PFS (HR 0.122; p<0.001); performance status was a major independent prognostic factor. Severe (≥G3) chemotherapy-related toxicities were more frequent in the ST group.

Conclusion

Our real-world data suggest a potential outcome advantage for integrating metastasis-directed locoregional treatment with systemic therapy in selected patients with synchronous oligometastatic esophageal/GEJ cancer, with a more consistent signal in SCC. While residual confounding cannot be excluded, the results provide a rationale for prospective validation and for incorporating histology into future trial design and multidisciplinary decision-making.

Zitieren

APA

Pittacolo, M., Moletta, L., Vittori, A., Capovilla, G., Nezi, G., Provenzano, L., Zanchettin, G., Pierobon, E. S., Murgioni, S., Nappo, F., Lonardi, S., Salvador, R., & Valmasoni, M. (2026). PD04.08. Impact of Locoregional Treatment in Synchronous Oligometastatic Esophageal Cancer: Evidence From a Real-World Cohort. Diseases of the Esophagus, 39(Supplement_1). https://doi.org/10.1093/dote/doag077.103

Vancouver

Pittacolo M, Moletta L, Vittori A, Capovilla G, Nezi G, Provenzano L, et al. PD04.08. Impact of Locoregional Treatment in Synchronous Oligometastatic Esophageal Cancer: Evidence From a Real-World Cohort. Diseases of the Esophagus. 2026;39(Supplement_1). doi:10.1093/dote/doag077.103

BibTeX
@article{Pittacolo2026,
  author = {Pittacolo, Matteo and Moletta, Lucia and Vittori, Arianna and Capovilla, Giovanni and Nezi, Giulia and Provenzano, Luca and Zanchettin, Gianpietro and Pierobon, Elisa Sefora and Murgioni, Sabina and Nappo, Floriana and Lonardi, Sara and Salvador, Renato and Valmasoni, Michele},
  title = {PD04.08. Impact of Locoregional Treatment in Synchronous Oligometastatic Esophageal Cancer: Evidence From a Real-World Cohort},
  journal = {Diseases of the Esophagus},
  year = {2026},
  volume = {39},
  number = {Supplement_1},
  doi = {10.1093/dote/doag077.103}
}
Kostenlos starten →